| Operations and Assets for Operating Segments and Geographic Information |
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended September 30, |
|
For the nine months ended September 30, |
(In thousands) |
2016 |
|
2015 |
|
2016 |
|
2015 |
Revenue from services: |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
— |
|
|
$ |
160 |
|
|
$ |
— |
|
|
$ |
192 |
|
Diagnostics |
259,025 |
|
|
103,739 |
|
|
777,559 |
|
|
107,597 |
|
Corporate |
— |
|
|
20 |
|
|
— |
|
|
140 |
|
|
$ |
259,025 |
|
|
$ |
103,919 |
|
|
$ |
777,559 |
|
|
$ |
107,929 |
|
Product revenues: |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
20,569 |
|
|
$ |
20,765 |
|
|
$ |
63,275 |
|
|
$ |
59,066 |
|
Diagnostics |
— |
|
|
— |
|
|
— |
|
|
— |
|
Corporate |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
$ |
20,569 |
|
|
$ |
20,765 |
|
|
$ |
63,275 |
|
|
$ |
59,066 |
|
Revenue from transfer of intellectual property: |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
18,441 |
|
|
$ |
18,350 |
|
|
$ |
105,338 |
|
|
$ |
48,552 |
|
Diagnostics |
— |
|
|
— |
|
|
— |
|
|
— |
|
Corporate |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
$ |
18,441 |
|
|
$ |
18,350 |
|
|
$ |
105,338 |
|
|
$ |
48,552 |
|
Operating income (loss): |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
(18,593 |
) |
|
$ |
5,300 |
|
|
$ |
15,422 |
|
|
$ |
(36,861 |
) |
Diagnostics |
3,098 |
|
|
(1,961 |
) |
|
11,117 |
|
|
(17,961 |
) |
Corporate |
(8,128 |
) |
|
(11,562 |
) |
|
(49,414 |
) |
|
(34,444 |
) |
Less: Operating loss attributable to noncontrolling interests |
— |
|
|
— |
|
|
— |
|
|
(1,281 |
) |
|
$ |
(23,623 |
) |
|
$ |
(8,223 |
) |
|
$ |
(22,875 |
) |
|
$ |
(90,547 |
) |
Depreciation and amortization: |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
6,994 |
|
|
$ |
2,775 |
|
|
$ |
12,841 |
|
|
$ |
6,902 |
|
Diagnostics |
18,818 |
|
|
9,602 |
|
|
59,711 |
|
|
13,103 |
|
Corporate |
20 |
|
|
22 |
|
|
60 |
|
|
68 |
|
|
$ |
25,832 |
|
|
$ |
12,399 |
|
|
$ |
72,612 |
|
|
$ |
20,073 |
|
Net income (loss) from investment in investees: |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
399 |
|
|
$ |
(3,502 |
) |
|
$ |
(5,643 |
) |
|
$ |
(6,067 |
) |
Diagnostics |
(1,213 |
) |
|
— |
|
|
496 |
|
|
— |
|
Corporate |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
$ |
(814 |
) |
|
$ |
(3,502 |
) |
|
$ |
(5,147 |
) |
|
$ |
(6,067 |
) |
Revenues: |
|
|
|
|
|
|
|
United States |
$ |
259,221 |
|
|
$ |
104,358 |
|
|
$ |
777,703 |
|
|
$ |
109,359 |
|
Ireland |
20,594 |
|
|
22,308 |
|
|
114,526 |
|
|
53,807 |
|
Chile |
9,936 |
|
|
7,779 |
|
|
26,516 |
|
|
22,929 |
|
Spain |
3,910 |
|
|
3,447 |
|
|
12,257 |
|
|
12,303 |
|
Israel |
3,699 |
|
|
4,154 |
|
|
12,862 |
|
|
14,309 |
|
Mexico |
675 |
|
|
988 |
|
|
2,308 |
|
|
2,840 |
|
|
$ |
298,035 |
|
|
$ |
143,034 |
|
|
$ |
946,172 |
|
|
$ |
215,547 |
|
|
|
|
|
|
|
|
|
|
(In thousands) |
September 30,
2016 |
|
December 31,
2015 |
Assets: |
|
|
|
Pharmaceutical |
$ |
1,318,377 |
|
|
$ |
1,234,752 |
|
Diagnostics |
1,412,726 |
|
|
1,421,034 |
|
Corporate |
68,924 |
|
|
143,402 |
|
|
$ |
2,800,027 |
|
|
$ |
2,799,188 |
|
Goodwill: |
|
|
|
Pharmaceutical |
$ |
257,570 |
|
|
$ |
251,225 |
|
Diagnostics |
442,956 |
|
|
492,123 |
|
Corporate |
— |
|
|
— |
|
|
$ |
700,526 |
|
|
$ |
743,348 |
|
|